Background: Treatments in patients with multidrug resistance often involve the use of multiple agents with\npartial antiviral activity and overlapping metabolic toxicities. Enfuvirtide is therefore a welcome addition to the\nantiretroviral management of patients with multiclass resistant virus, given the low risk of systemic toxicities and\nnovel mechanism of action relative to existing drug classes.\nThe aim of this study was to evaluate the effectiveness of ENF plus optimized background regimen (OBR) in a\nMexican cohort of highly HIV-1 ARV-experienced patients.\nMethods: Prospective cohort of treatment-experienced HIV-1-infected adults with virological failure who started\ntherapy with an ENF-containing regimen. The effectiveness of ENF treatment was evaluated with percentages of\nundetectable HIV-1 RNA viral load after 24 and 48 weeks of treatment, and changes in CD4+ cell counts.\nResults: Forty patients >18 years were included. After 24 weeks of treatment, 91% of patients had HIV-1 RNA viral\nload <400 copies/mL and 65.8% had <50 copies/mL. At week 48 of treatment, 81.4% of the patients had HIV-1 RNA\n<400 copies/mL and 55.5% had <50 copies/mL; in both cases p <0.0001 compared to baseline. Increase CD4+ cells\nwere also statistically significant at weeks 24 and 48 with respect to the baseline. Pain at the site of injection was\nthe main adverse event in 100% of patients.\nConclusion: Our study provides clinically important evidence of the effectiveness and safety of ENF in highly\nARV-experienced HIV-1-infected patients. These findings strengthen the results of previous randomized controlled\ntrials with this agent.
Loading....